6th Jan 2022 17:59
PureTech Health PLC - clinical-stage biotherapeutics company - In a randomised, double-blind crossover study in older adults, results demonstrated that 50% fewer subjects treated with PureTech's LYT-100 - also known as deupirfenidone - experience gastrointestinal-related adverse events compared to those treated with pirfenidone.
Pirfenidone is the treatment approved by the US Food & Drug Administration for idiopathic pulmonary fibrosis, a disease which can lean to significant morbidity and mortality.
PureTech is seeking to advance LYT-100 into late-stage clinical development for the treatment of IPF, starting with a dose-ranging study evaluating six months of treatment, which is due to start in the first half of 2022.
"In the recently completed healthy older adult study, LYT-100 administration resulted in a clinically meaningful 50% reduction in the number of healthy older adults experiencing GI-related adverse events, compared to pirfenidone. This underscores the potential of LYT-100 to address a significant unmet need for patients with IPF by offering a more tolerable treatment option that may allow patients to continue on therapy, which is critical to address this serious condition," says Chief Medical Officer Julie Krop.
Current stock price: 287.03 pence
12-month change: down 28%
By Dayo Laniyan; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech